- Analytica Investor
- Posts
- 📊 Vor Biopharma Soars, I-Mab Dips, Altimmune & Opendoor Tops the Trading Volume
📊 Vor Biopharma Soars, I-Mab Dips, Altimmune & Opendoor Tops the Trading Volume
Dive into the movers and shakers on the stock market - who's gained, who's lost, and why.
Matthias Schneider
June 27, 2025
Good Morning Investors,
Hello Market Enthusiasts, it's been another cork-popping day for Vor Biopharma Inc $VOR ( ▲ 31.72% ) with shares skyrocketing thanks to the unveiling of a $175 million private funding round and a shiny new global licensing agreement.
On the flip side, I-Mab $IMAB ( ▼ 6.11% ) saw a sharp decline, with positive Phase 1b data for Givastomig sparking unexpected investor reactions. High-volume trades enveloped Altimmune Inc $ALT ( ▼ 2.86% ) and Opendoor Technologies Inc $OPEN ( ▲ 7.74% ) , both clocking significant shares traded. Without further ado, let's dive in for a closer look at these Wall Street roller-coasters.
Matthias Schneider
Editor at Analytica Investor